ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties

ABVC BIOPHARMA, INC.

ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.
Upfront license fee of $12.5M (cash or OncoX shares) due in 30 days; additional $1.25M milestone after OncoX's next fundraising (no guarantee).
ABVC entitled to 5% royalties on net sales, capped at $12.5M, after product launch (uncertain).
BLEX 404 is a β-glucan extract from Maitake mushroom; FDA has approved four INDs for ABVC's oncology pipeline including ABV-1702 for MDS.
No guarantee any fees or royalties will be received; partnership is early-stage and contingent on OncoX's fundraising and commercial success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.